BNTC: BB-301 clinical progress and robust cash reserves highlight a year of operational and financial momentum
BB-301 clinical development advanced with full enrollment of Cohort 2 and positive interim results, while a strong cash position of $180 million supports ongoing operations. Net loss widened to $45.5 million as R&D and G&A expenses increased year-over-year.Original document: Benitec Biopharma Inc…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.